Intraclot recombinant tissue-type plasminogen activator reduces perihematomal edema and mortality in patients with spontaneous intracerebral hemorrhage

Abstract

The study aimed to investigate the impact of intraclot recombinant tissue-type plasminogen activator (rt-PA) on perihematomal edema (PHE) development in patients with intracerebral hemorrhage (ICH) treated with minimally invasive surgery (MIS) and the effects of intraclot rt-PA on the 30-day survival. We reviewed the medical records of ICH patients undergoing MIS between October 2011 and July 2013. A volumetric analysis was done to assess the change in PHE and ICH volumes at pre-MIS (T₁), post-MIS (T₂) and day 10–16 (T₃) following diagnostic computed tomographic scans (T₀). Forty-three patients aged 52.8±11.1 years with (n=30) or without rt-PA (n=13) were enrolled from our institutional ICH database. The median rt-PA dose was 1.5 (1) mg, with a maximum dose of 4.0 mg. The ratio of clot evacuation was significantly increased by intraclot rt-PA as compared with controls (77.9%±20.4% vs. 64%±15%; P=0.046). From T₁ to T₂, reduction in PHE volume was strongly associated with the percentage of clot evacuation (ρ=0.34; P=0.027). In addition, PHE volume was positively correlated with residual ICH volume at the same day (ρ ranging from 0.39–0.56, P<0.01). There was no correlation between the cumulative dose of rt-PA and early (T₂) PHE volume (ρ=0.24; P=0.12) or delayed (T₃) PHE volume (ρ=0.19; P=0.16). The 30-day mortality was zero in this cohort. In the selected cohort of ICH patients treated with MIS, intraclot rt-PA accelerated clot removal and had no effects on PHE formation. MIS aspiration and low dose of rt-PA seemed to be feasible to reduce the 30-day mortality in patients with severe ICH. A large, randomized study addressing dose titration and long-term outcome is needed.

Keywords

intracerebral hemorrhage / minimally invasive surgery / clot aspiration / perihematomal edema / recombinant tissue-type plasminogen activator

References

[1] van AschCJ, LuitseMJ, RinkelGJ, et al.. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol, 2010, 9(2): 167-176

[2] ArimaH, WangJG, HuangY, et al.. Significance of perihematomal edema in acute intracerebral hemorrhage: the INTERACT trial. Neurology, 2009, 73(23): 1963-1968

[3] BroderickJP, BrottTG, DuldnerJE, et al.. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke, 1993, 24(7): 987-993

[4] StaykovD, WagnerI, VolbersB, et al.. Natural course of perihemorrhagic edema after intracerebral hemorrhage. Stroke, 2011, 42(9): 2625-2629

[5] ZazuliaAR, DiringerMN, DerdeynCP, et al.. Progression of mass effect after intracerebral hemorrhage. Stroke, 1999, 30(6): 1167-1173

[6] CarhuapomaJR, BarrettRJ, KeylPM, et al.. Stereotactic aspiration-thrombolysis of intracerebral hemorrhage and its impact on perihematoma brain edema. Neurocrit Care, 2008, 8(3): 322-329

[7] MouldWA, CarhuapomaJR, MuschelliJ, et al.. Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema. Stroke, 2013, 44(3): 627-634

[8] WagnerKR, XiG, HuaY, et al.. Ultra-early clot aspiration after lysis with tissue plasminogen activator in a porcine model of intracerebral hemorrhage: edema reduction and blood-brain barrier protection. J Neurosurg, 1999, 90(3): 491-498

[9] BarrettRJ, HussainR, CoplinWM, et al.. Frameless stereotactic aspiration and thrombolysis of spontaneous intracerebral hemorrhage. Neurocrit Care, 2005, 3(3): 237-245

[10] VespaP, McArthurD, MillerC, et al.. Frameless stereotactic aspiration and thrombolysis of deep intracerebral hemorrhage is associated with reduction of hemorrhage volume and neurological improvement. Neurocrit Care, 2005, 2(3): 274-281

[11] FigueroaBE, KeepRF, BetzAL, et al.. Plasminogen activators potentiate thrombin-induced brain injury. Stroke, 1998, 29(6): 1202-1207

[12] RohdeV, RohdeI, ThiexR, et al.. Fibrinolysis therapy achieved with tissue plasminogen activator and aspiration of the liquefied clot after experimental intracerebral hemorrhage: rapid reduction in hematoma volume but intensification of delayed edema formation. J Neurosurg, 2002, 97(4): 954-962

[13] RohdeV, UzmaN, ThiexR, et al.. Management of delayed edema formation after fibrinolytic therapy for intracerebral hematomas: preliminary experimental data. Acta Neurochir Suppl, 2008, 105: 101-104

[14] ThiexR, KukerW, MullerHD, et al.. The long-term effect of recombinant tissue-plasminogen-activator (rt-PA) on edema formation in a large-animal model of intracerebral hemorrhage. Neurol Res, 2003, 25(3): 254-262

[15] ThiexR, WeisJ, KringsT, et al.. Addition of intravenous N-methyl-D-aspartate receptor antagonists to local fibrinolytic therapy for the optimal treatment of experimental intracerebral hemorrhages. J Neurosurg, 2007, 106(2): 314-320

[16] DucruetAF, HickmanZL, ZachariaBE, et al.. Exacerbation of perihematomal edema and sterile meningitis with intraventricular administration of tissue plasminogen activator in patients with intracerebral hemorrhage. Neurosurgery, 2010, 66(4): 648-655

[17] TangZP, ShiYH, YinXP, et al.. Modifying the details of aspiration operation may contribute to the improvement of prognosis of patients with ICH. Turk Neurosurg, 2012, 22(1): 13-20

[18] XiaoB, WuFF, ZhangH, et al.. A randomized study of urgent computed tomography-based hematoma puncture and aspiration in the emergency department and subsequent evacuation using craniectomy versus craniectomy only. J Neurosurg, 2012, 117(3): 566-573

[19] XuF, TangZ, LuoX, et al.. No evidence of preoperative hematoma growth representing an increased postoperative rebleeding risk for minimally invasive aspiration and thrombolysis of ICH. Br J Neurosurg, 2010, 24(3): 268-274

[20] MorgensternLB, HemphillJC3rd, AndersonC, et al.. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2010, 41(9): 2108-2129

[21] HemphillJC3rd, BonovichDC, BesmertisL, et al.. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke, 2001, 32(4): 891-897

[22] KeepRF, HuaY, XiG. Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol, 2012, 11(8): 720-731

[23] MayerSA, SaccoRL, ShiT, et al.. Neurologic deterioration in noncomatose patients with supratentorial intracerebral hemorrhage. Neurology, 1994, 44(8): 1379-1384

[24] NaffN, WilliamsMA, KeylPM, et al.. Low-dose recombinant tissue-type plasminogen activator enhances clot resolution in brain hemorrhage: the intraventricular hemorrhage thrombolysis trial. Stroke, 2011, 42(11): 3009-3016

[25] StaykovD, WagnerI, VolbersB, et al.. Dose effect of intraventricular fibrinolysis in ventricular hemorrhage. Stroke, 2011, 42(7): 2061-2064

[26] GodoyDA, PineroG, Di NapoliM. Predicting mortality in spontaneous intracerebral hemorrhage: can modification to original score improve the prediction?. Stroke, 2006, 37(4): 1038-1044

[27] WangW, LuJ, WangC, et al.. Prognostic value of ICH score and ICH-GS score in Chinese intracerebral hemorrhagepatients: analysis from the China National Stroke Registry (CNSR). PLoS One, 2013, 8(10): e77421

[28] HerrickDB, ZiaiWC, ThompsonCB, et al.. Systemic hematologic status following intraventricular recom-binant tissue-type plasminogen activator for intra-ventricular hemorrhage: the CLEAR IVH Study Group. Stroke, 2011, 42(12): 3631-3633

[29] ZimmermanRD, MaldjianJA, BrunNC, et al.. Radiologic estimation of hematoma volume in intracerebral hemorrhage trial by CT scan. AJNR Am J Neuroradiol, 2006, 27(3): 666-670